Full history for every metric is available with a Kvantra account
Forma Therapeutics Holdings, Inc. (FMTX)
Key financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | 164 | 101 | 0 | 0 | 0 |
| Operating profit | $m | -173 | -189 | |||||
| Net profit | $m | - | - | 5 | -35 | -70 | -173 | -190 |
| EPS reported | $ | -4.21 | -4.00 | |||||
| Operating cashflow per share | $ | -3.65 | -3.65 | |||||
| Capex per share | $ | 0.10 | 0.10 | |||||
| FCF per share | $ | -3.75 | -3.75 | |||||
| Free cash flow | $m | -154 | -175 | |||||
| Net debt | $m | -431 | -396 | |||||
| Book value equity | $m | 498 | 414 | |||||
| Book value per share | $ | 12.13 | 8.67 | |||||
| Number of shares | m | 41.09 | 47.81 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.17 | 2.31 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -3.79 | -5.46 | |||||
| EV/EBITDA LTM | x | -3.15 | -3.00 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -29.60% | -21.04% | |||||
| FCF Yield | % | -26.35% | -18.31% | |||||
| Quality | ||||||||
| ROE | % | -34.71% | -30.17% | |||||
| ROIC | % | -32.54% | -32.54% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -4.70 | -5.38 | |||||
| Net Debt/EBITDA | x | 0.26 | 0.26 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -73.85% | -41.39% | |||||
| Net debt/Equity | x | -0.87 | -0.96 | |||||
| Gross debt/equity | x | 0.07 | 0.08 | |||||
Company overview
Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing groundbreaking therapies for rare hematologic conditions and various cancers. Its lead development candidates include FT-4202, undergoing Phase 1 trials for sickle cell disease and other hemoglobinopathies, and FT-7051, targeting metastatic castration-resistant prostate cancer. The company is also progressing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 (IDH1) gene mutations, currently in Phase II for relapsed/refractory acute myeloid leukemia and Phase I for glioma. Furthermore, Forma is developing FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to disrupt de novo lipogenesis in the liver. Founded in 2007 and headquartered in Watertown, Massachusetts, Forma Therapeutics Holdings, Inc. has operated as a subsidiary of Novo Nordisk A/S since October 14, 2022.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Forma Therapeutics Holdings, Inc. (FMTX)
Forma Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing groundbreaking therapies for rare hematologic conditions and various cancers. Its lead development candidates include FT-4202, undergoing Phase 1 trials for sickle cell disease and other hemoglobinopathies, and FT-7051, targeting metastatic castration-resistant prostate cancer. The company is also progressing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 (IDH1) gene mutations, currently in Phase II for relapsed/refractory acute myeloid leukemia and Phase I for glioma. Furthermore, Forma is developing FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to disrupt de novo lipogenesis in the liver. Founded in 2007 and headquartered in Watertown, Massachusetts, Forma Therapeutics Holdings, Inc. has operated as a subsidiary of Novo Nordisk A/S since October 14, 2022.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free